The Safety/Efficacy of hUC Mesenchymal Stem Cells(19#iSCLife®-OA) Therapy for Patients With Osteoarthritis

Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
AgeUp to 70
SponsorSclnow Biotechnology Co., Ltd.

About this trial

The purpose of this study is verify the efficacy and safety of Human Umbilical Cord Mesenchymal Stem Cells (UC-MSC) therapy for patients with Osteoarthritis, and in addition, provide basis for exploring the treatment regimen of UC-MSC therapy in different degree of cartilage defect disease

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Diagnosis of Knee Osteoarthritis by Kellgren and Lawrence Grading Scale, classified with Grade 2-3

Confirm with cartilage injury,articular cartilage part or full-thickness injury, by MR (Magnetic Resonance)

Age <70, no serious organ dysfunction

Over 2 years knee pain or no very effective with conservative treatments

Disqualifiers

Refuse to sign the consent form, or cannot keep follow-up visit

Age >70; Age <70, but with multiple organ failure

Unstable vital signs (breath, blood pressure, pulse)

Combined with knee ligament (anterior and the posterior cruciate ligament, medial and lateral collateral ligament) rupture, laxity, etc.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Low dose mesenchymal stem cells

    Biological/Vaccine

    Human umbilical cord mesenchymal stem cells (SCLnow 19#): group A, 1 \* 10\^7 cells (5ml);

  • High dose mesenchymal stem cells

    Biological/Vaccine

    Human umbilical cord mesenchymal stem cells (SCLnow 19#): group B, 2 \* 10\^7 cells (5ml)

  • Intraarticular injection

    Procedure/Surgery

    Intraarticular injection with human umbilical cord mesenchymal stem cells (SCLnow 19#) with different dose group

Treatment groups

60 Participants
are divided into 3 treatment groups
Group A: Low dose mesenchymal stem cellsExperimental treatment 2 interventions
Group B: High dose mesenchymal stem cellsExperimental treatment 2 interventions
Group C: Control groupsNo intervention 0 interventions

Trial outcomes

Primary outcomes

1

Kellgren-Lawrence Grading Scale

Using Magnetic Resonance Imaging (MRI) examination, and based on the images of bilateral knee joint, grade by Kellgren-Lawrence Grading Scale. Kellgren-Lawrence Grading Scale is a method of classifying the severity of knee osteoarthritis (OA). Grade 0: No radiographic features of osteoarthritis; Grade 1: Possible joint space narrowing (normal joint space is at least 2 mm at the superior acetabulum) and osteophyte formation; Grade 2: Definite osteophyte formation with possible joint space narrowing; Grade 3: Multiple osteophytes, definite joint space narrowing, sclerosis and possible bony deformity; Grade 4: Large osteophytes, marked joint space narrowing, severe sclerosis and definite bony deformity.

Time frame
12 months

Secondary outcomes

1

Assessment of Preoperative Cartilage Defect Severity (AMADEUS)

Using Magnetic Resonance Imaging (MRI) examination to diagnose patients by Assessment of Preoperative Cartilage Defect Severity (AMADEUS).

Time frame
12 months
2

Lysholm scoring

Using Lysholm Knee Scoring Scale to grade the knee function of patients, and examine the changes or improvement compare to baseline.

Time frame
12 months
3

The international knee documentation committee (IKDC) knee evaluation form

The international knee documentation committee knee evaluation form is used to assess the knee function of patients, examine the changes or improvement compare to baseline.

Time frame
12 months
4

Visual Analogue Scale/Score(VAS)

Using Visual Analogue Scale/Score for pain to examine the change/improvement of knee joint function.

Time frame
12 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.